Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Angiopoietin-1 mimetics: new therapeutic agents for cancer treatment.

EF 2010-11

Résumé
Traditional chemotherapy targets cancer cells. A newer class of cancer treatment called anti-angiogenic cancer therapy seeks to restrict the development of a solid tumour's blood supply, effectively inhibiting a tumour's growth by suffocating it. Most anti-angiogenic agents that have received FDA approval for cancer treatment in the past decade have a mechanism of action that inhibits the vascular endothelial growth factor (VEGF) pathway. Other than VEGF, another protein family that regulates blood vessel growth is the angiopoietin family, which includes Ang1 (a 'blood vessel stabilizer' that reduces vessel leakiness and keep vessels quiescent) and Ang2 (a 'blood vessel destabilizer' that renders vessels leaky and initiates new capillary growth). In recent years, preclinical and early clinical studies have started investigating the use of Ang2 inhibitors (anti-Ang2 agents) as anti-angiogenic cancer therapeutic agents. While inhibitors of the VEGF and Ang2 pathways are designed to limit the growth of tumours once tumour cells have seeded into body organs, another potential anti-cancer strategy is to target the metastatic process - by preventing circulating tumour cells from escaping blood vessels and seeding into body tissues in the first place. Here we hypothesize that Ang1 mimetics (pro-Ang1 agents) - engineered peptides that recapitulate endogenous Ang1's ability to activate its endothelial receptor, Tie2, thereby inducing Ang1 effects - may serve as a new class of vascular-targeting cancer therapeutics with anti-metastatic capacity through their ability to stabilize host microvascular beds. Hence we propose to investigate the potential anti-tumour and anti-metastatic efficacy of Ang1 mimetics, using mouse models of cancer, when administered as single agents and in combination with traditional chemotherapy or VEGF/Ang2 pathway-targeted agents.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
217998
Name
Wu Florence T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Angiopoietin-1 mimetics: new therapeutic agents for cancer treatment.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Angiopoietin Ligands; Anti-Metastatic Agents; Anti-Tumor Agents; Endothelium-Targeted Cancer Treatment; Mouse Models; Tie Receptors; Vascular Endothelial Growth Factors
Abstract
Traditional chemotherapy targets cancer cells. A newer class of cancer treatment called anti-angiogenic cancer therapy seeks to restrict the development of a solid tumour's blood supply, effectively inhibiting a tumour's growth by suffocating it. Most anti-angiogenic agents that have received FDA approval for cancer treatment in the past decade have a mechanism of action that inhibits the vascular endothelial growth factor (VEGF) pathway. Other than VEGF, another protein family that regulates blood vessel growth is the angiopoietin family, which includes Ang1 (a 'blood vessel stabilizer' that reduces vessel leakiness and keep vessels quiescent) and Ang2 (a 'blood vessel destabilizer' that renders vessels leaky and initiates new capillary growth). In recent years, preclinical and early clinical studies have started investigating the use of Ang2 inhibitors (anti-Ang2 agents) as anti-angiogenic cancer therapeutic agents. While inhibitors of the VEGF and Ang2 pathways are designed to limit the growth of tumours once tumour cells have seeded into body organs, another potential anti-cancer strategy is to target the metastatic process - by preventing circulating tumour cells from escaping blood vessels and seeding into body tissues in the first place. Here we hypothesize that Ang1 mimetics (pro-Ang1 agents) - engineered peptides that recapitulate endogenous Ang1's ability to activate its endothelial receptor, Tie2, thereby inducing Ang1 effects - may serve as a new class of vascular-targeting cancer therapeutics with anti-metastatic capacity through their ability to stabilize host microvascular beds. Hence we propose to investigate the potential anti-tumour and anti-metastatic efficacy of Ang1 mimetics, using mouse models of cancer, when administered as single agents and in combination with traditional chemotherapy or VEGF/Ang2 pathway-targeted agents.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wu, Florence T
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~